Antitrust Counsel to Allergan in $40.5 Billion Generics Sale to Teva

July 27, 2015

Cleary Gottlieb advised Allergan on international competition law matters outside the United States and Canada and certain financing-related matters in connection with the $40.5 billion sale of Allergan’s global generic pharmaceuticals business to Teva, which was announced today. Allergan will retain its dynamic global branded pharmaceutical and medical aesthetic businesses, as well as its biosimilars development programs and the Anda distribution business.